

藥敏判讀標準(GNB)

Enterobacterales (不含 <i>Salmonella</i> spp./ <i>Shigella</i> spp.)							
抗生素分類		抗生素(µg/ml)	S	SDD	I	R	判讀標準及版本
β-lactam combination agents	SAM	Ampicillin/Sulbactam	≤8/4	-	16/8 [^]	≥32/16	CLSI M100-Ed32 (Group B)
	TZP	Piperacillin/Tazobactam	≤8/4	16/4	-	≥32/4	CLSI M100-Ed32 (Group B)
Cephalosporins I		Cefazolin ^a	≤2	-	4	≥8	CLSI M100-Ed32 (Group A)
	CZ	Cefazolin (Urine) (for <i>K.p.</i> , <i>E. coli</i> , <i>P.m.</i>) ^b	≤16	-	-	≥32	CLSI M100-Ed32 (Group U)
Cephameycins	CMZ	Cefmetazole	≤ 16	-	32 [^]	≥ 64	CLSI M100-Ed32 (Group O)
Cephalosporins III	CTX	Cefotaxime	≤1	-	2 [^]	≥4	CLSI M100-Ed32 (Group B)
	CAZ	Ceftazidime	≤4	-	8 [^]	≥16	CLSI M100-Ed32 (Group C)
Cephalosporins IV	FEP	Cefepime	≤2	4-8	-	≥16	CLSI M100-Ed32 (Group B)
Carbapenems	ETP	Ertapenem	≤0.5	-	1 [^]	≥2	CLSI M100-Ed32 (Group B)
	IPM	Imipenem	≤1	-	2 [^]	≥4	CLSI M100-Ed32 (Group B)
	MEM	Meropenem	≤1	-	2 [^]	≥4	CLSI M100-Ed32 (Group B)
Aminoglycosides	GM	Gentamicin	≤4	-	8 [^]	≥16	CLSI M100-Ed32 (Group A)
	AN	Amikacin	≤ 16	-	32 [^]	≥ 64	CLSI M100-Ed32 (Group B)
Folate pathway antagonists	SXT	Trimethoprim/sulfamethoxazole	≤2/38	-	-	≥4/76	CLSI M100-Ed32 (Group B)
Lipopeptide	CL	Colistin	-	-	≤2	≥4	CLSI M100-Ed32 (Group O)
Fluoroquinolones	CIP	Ciprofloxacin	≤0.25	-	0.5 [^]	≥1	CLSI M100-Ed32 (Group B)
	LVX	Levofloxacin	≤0.5	-	1 [^]	≥2	CLSI M100-Ed32 (Group B)
Tetracyclines	TGC	Tigecycline	≤2	-	4	≥8	FDA (2023年版)

[^] : 抗生素可能集中在某個身體部位，僅適用informational use

a. 判讀標準適用菌株: *Enterobacterales*，但不包含 *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis* 引起的uncomplicated UTI。

b. 判讀標準適用菌株: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis* 引起的uncomplicated UTI。

Salmonella spp./Shigella spp.

抗生素分類	抗生素(μg/ml)	S	SDD	I	R	判讀標準及版本
Cephalosporins III	CTX Cefotaxime	≤1	-	2 [^]	≥4	CLSI M100-Ed32 (Group B)
Folate pathway antagonists	SXT Trimethoprim/sulfamethoxazole	≤2/38	-	-	≥4/76	CLSI M100-Ed32 (Group B)
Fluoroquinolones	CIP Ciprofloxacin	≤0.06	-	0.12-0.5 [^]	≥1	CLSI M100-Ed32 (Group B)
	LVX Levofloxacin	≤0.12	-	0.25-1 [^]	≥2	CLSI M100-Ed32 (Group B)

<i>Pseudomonas aeruginosa</i>						
抗生素分類	抗生素(μg/ml)		S	I	R	判讀標準及版本
β-lactam combination agents	TZP	Piperacillin/Tazobactam	≤16/4	32/4-64/4 [^]	≥128/4	CLSI M100-Ed32 (Group A)
Cephalosporins III	CAZ	Ceftazidime	≤8	16 [^]	≥32	CLSI M100-Ed32 (Group A)
Cephalosporins IV	FEP	Cefepime	≤8	16 [^]	≥32	CLSI M100-Ed32 (Group B)
Carbapenems	IPM	Imipenem	≤2	4 [^]	≥8	CLSI M100-Ed32 (Group B)
	MEM	Meropenem	≤2	4 [^]	≥8	CLSI M100-Ed32 (Group B)
Aminoglycosides	GM	Gentamicin	≤4	8 [^]	≥16	CLSI M100-Ed32 (Group A)
	AN	Amikacin	≤16	32 [^]	≥64	CLSI M100-Ed32 (Group B)
Lipopeptide	CL	Colistin	-	≤2	≥4	CLSI M100-Ed32 (Group O)
Fluoroquinolones	CIP	Ciprofloxacin	≤0.5	1 [^]	≥2	CLSI M100-Ed32 (Group B)
	LVX	Levofloxacin	≤1	2 [^]	≥4	CLSI M100-Ed32 (Group B)

<i>Acinetobacter</i> spp.						
抗生素分類	抗生素(μg/ml)		S	I	R	判讀標準及版本
β-lactam combination agents	SAM	Ampicillin/Sulbactam	≤8/4	16/8	≥32/16	CLSI M100-Ed32 (Group A)
	TZP	Piperacillin/Tazobactam	≤16/4	32/4-64/4	≥128/4	CLSI M100-Ed32 (Group B)
Cephalosporins III	CTX	Cefotaxime	≤8	16-32	≥64	CLSI M100-Ed32 (Group B)
	CAZ	Ceftazidime	≤8	16	≥32	CLSI M100-Ed32 (Group A)
Cephalosporins IV	FEP	Cefepime	≤8	16	≥32	CLSI M100-Ed32 (Group B)
Carbapenems	IPM	Imipenem	≤2	4	≥8	CLSI M100-Ed32 (Group A)
	MEM	Meropenem	≤2	4	≥8	CLSI M100-Ed32 (Group A)
Aminoglycosides	GM	Gentamicin	≤4	8	≥16	CLSI M100-Ed32 (Group A)
	AN	Amikacin	≤16	32	≥64	CLSI M100-Ed32 (Group B)
Folate pathway antagonists	SXT	Trimethoprim/sulfamethoxazole	≤2/38	—	≥4/76	CLSI M100-Ed32 (Group B)
Lipopeptide	CL	Colistin	-	≤2	≥4	CLSI M100-Ed32 (Group O)
Fluoroquinolones	CIP	Ciprofloxacin	≤1	2	≥4	CLSI M100-Ed32 (Group A)
	LVX	Levofloxacin	≤2	4	≥8	CLSI M100-Ed32 (Group A)
Tetracyclines	TGC	Tigecycline	≤1	2	≥4	BSAC (2009年)

<i>Burkholderia cepacia</i> complex						
抗生素分類	抗生素($\mu\text{g/ml}$)		S	I	R	判讀標準及版本
Cephalosporins III	CAZ	Ceftazidime	≤ 8	16	≥ 32	CLSI M100-Ed32 (Group B)
Carbapenems	MEM	Meropenem	≤ 4	8	≥ 16	CLSI M100-Ed32 (Group A)
Folate pathway antagonists	SXT	Trimethoprim/sulfamethoxazole	$\leq 2/38$	-	$\geq 4/76$	CLSI M100-Ed32 (Group A)
Fluoroquinolones	LVX	Levofloxacin	≤ 2	4	≥ 8	CLSI M100-Ed32 (Group A)

Stenotrophomonas maltophilia

抗生素分類		抗生素($\mu\text{g/ml}$)	S	I	R	判讀標準及版本
Cephalosporins III	CAZ	Ceftazidime	≤ 8	16	≥ 32	CLSI M100-Ed32 (Group B)
Folate pathway antagonists	SXT	Trimethoprim/sulfamethoxazole	$\leq 2/38$	—	$\geq 4/76$	CLSI M100-Ed32 (Group A)
Fluoroquinolones	LVX	Levofloxacin	≤ 2	4	≥ 8	CLSI M100-Ed32 (Group A)

Aeromonas spp.						
抗生素分類	抗生素($\mu\text{g/ml}$)		S	I	R	判讀標準及版本
β -lactam combination agents	TZP	Piperacillin/Tazobactam	$\leq 16/4$	32/4-64/4	$\geq 128/4$	M45-Ed3
Cephalosporins III	CTX	Cefotaxime	≤ 1	2	≥ 4	M45-Ed3
	CAZ	Ceftazidime	≤ 4	8	≥ 16	M45-Ed3
Cephalosporins IV	FEP	Cefepime	≤ 2	4-8	≥ 16	M45-Ed3
Carbapenems	ETP	Ertapenem	≤ 0.5	1	≥ 2	M45-Ed3
	IPM	Imipenem	≤ 1	2	≥ 4	M45-Ed3
	MEM	Meropenem	≤ 1	2	≥ 4	M45-Ed3
Aminoglycosides	GM	Gentamicin	≤ 4	8	≥ 16	M45-Ed3
	AN	Amikacin	≤ 16	32	≥ 64	M45-Ed3
Folate pathway antagonists	SXT	Trimethoprim/sulfamethoxazole	$\leq 2/38$	-	$\geq 4/76$	M45-Ed3
Fluoroquinolones	CIP	Ciprofloxacin	≤ 1	2	≥ 4	M45-Ed3
	LVX	Levofloxacin	≤ 2	4	≥ 8	M45-Ed3

Vibrio spp.						
抗生素分類	抗生素($\mu\text{g/ml}$)		S	I	R	判讀標準及版本
β -lactam combination agents	TZP	Piperacillin/Tazobactam	$\leq 16/4$	32/4-64/4	$\geq 128/4$	M45-Ed3
Cephalosporins I	CZ	Cefazolin	≤ 2	4	≥ 8	M45-Ed3
Cephalosporins III	CTX	Cefotaxime	≤ 1	2	≥ 4	M45-Ed3
	CAZ	Ceftazidime	≤ 4	8	≥ 16	M45-Ed3
Cephalosporins IV	FEP	Cefepime	≤ 2	4-8	≥ 16	M45-Ed3
Carbapenems	IPM	Imipenem	≤ 1	2	≥ 4	M45-Ed3
	MEM	Meropenem	≤ 1	2	≥ 4	M45-Ed3
Aminoglycosides	GM	Gentamicin	≤ 4	8	≥ 16	M45-Ed3
	AN	Amikacin	≤ 16	32	≥ 64	M45-Ed3
Folate pathway antagonists	SXT	Trimethoprim/sulfamethoxazole	$\leq 2/38$	-	$\geq 4/76$	M45-Ed3
Fluoroquinolones	CIP	Ciprofloxacin	≤ 1	2	≥ 4	M45-Ed3
	LVX	Levofloxacin	≤ 2	4	≥ 8	M45-Ed3

Other non-Enterobacterales ^a						
抗生素分類		抗生素(µg/ml)	S	I	R	判讀標準及版本
β-lactam combination agents	TZP	Piperacillin/Tazobactam	≤16/4	32/4-64/4	≥128/4	CLSI M100-Ed32 (Group B)
Cephalosporins III	CTX	Cefotaxime	≤8	16-32	≥64	CLSI M100-Ed32 (Group C)
	CAZ	Ceftazidime	≤8	16	≥32	CLSI M100-Ed32 (Group A)
Cephalosporins IV	FEP	Cefepime	≤8	16	≥32	CLSI M100-Ed32 (Group B)
Carbapenems	IPM	Imipenem	≤4	8	≥16	CLSI M100-Ed32 (Group B)
	MEM	Meropenem	≤4	8	≥16	CLSI M100-Ed32 (Group B)
Aminoglycosides	GM	Gentamicin	≤4	8	≥16	CLSI M100-Ed32 (Group A)
	AN	Amikacin	≤16	32	≥64	CLSI M100-Ed32 (Group B)
Folate pathway antagonists	SXT	Trimethoprim/sulfamethoxazole	≤2/38	-	≥4/76	CLSI M100-Ed32 (Group B)
Fluoroquinolones	CIP	Ciprofloxacin	≤1	2	≥4	CLSI M100-Ed32 (Group B)
	LVX	Levofloxacin	≤2	4	≥8	CLSI M100-Ed32 (Group B)

a. Other non-Enterobacterales 包含 *Pseudomonas* spp. 與其他非挑別性葡萄糖非發酵性菌，但不包含 *P.aeruginosa*、*Acinetobacter* spp.、*B.cepacia* complex, *S. maltophilia*, *Aeromonas* spp., *Vibrio* spp.